Tilray | TRLY - PE Price to Earnings


Tilray reported 11.56 in PE Price to Earnings for its fiscal quarter ending in September of 2025.





Pe Change Date
Acasti Pharma 9.94 0.08 Mar/2021
Akebia Therapeutics 1.63K 1.6K Dec/2025
Aurora Cannabis 23.27 0 Mar/2026
Cronos Group 120.93 97.04 Mar/2026
Dianthus Therapeutics 3.8 1.53 Sep/2024
Divis Laboratories Ltd 59.75 6.76 Mar/2026
Ionis Pharmaceuticals 396.15 79.28 Sep/2022
IQVIA Holdings 19.37 7.21 Mar/2026
Knight Therapeutics 257.34 166.24 Dec/2025
Moderna 27.22 14.51 Jun/2023
Organigram Holdings 12.01 222.99 Mar/2026
Organon & Co 8.32 4.57 Mar/2026
Revvity 30.79 19.08 Mar/2026
Tectonic Therapeutic 4.01 0.63 Mar/2024
Tilray 11.56 80.19 Sep/2025
Viatris 14.61 4.21 Mar/2026
Xeris Pharmaceuticals 76.05 2.37K Mar/2026
Zealand Pharma A/S 5.13 0.16 Dec/2025